- Home
- BNR vs DHF Comparison
BNR vs DHF Comparison
Compare BNR & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNR | DHF |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.9M | 185.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BNR | DHF |
|---|---|---|
| Price | $23.40 | $2.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.2K | ★ 451.1K |
| Earning Date | 11-20-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,749,382.00 | N/A |
| Revenue This Year | $136.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.56 | N/A |
| 52 Week Low | $2.18 | $2.06 |
| 52 Week High | $24.92 | $2.39 |
Technical Indicators
Market Signals| Indicator | BNR | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 58.13 | 54.18 |
| Support Level | $19.10 | $2.47 |
| Resistance Level | $24.92 | $2.54 |
| Average True Range (ATR) | 2.36 | 0.03 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 67.01 | 75.00 |
Price Performance
Historical ComparisonAbout BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.